Valuation: MacroGenics, Inc.

Market Cap 153M 137M 126M 114M 213M 14.52B 217M 1.5B 603M 7.64B 574M 562M 24.08B P/E 2026 *
-1.54x
P/E 2027 * -1.46x
Enterprise Value 153M 137M 126M 114M 213M 14.52B 217M 1.5B 603M 7.64B 574M 562M 24.08B EV / Sales 2026 *
1.41x
EV / Sales 2027 * 1.69x
Free-Float
96.51%
Yield 2026 *
-
Yield 2027 * -
10-26 MacroGenics, Inc. Announces Positive Interim Phase 2 LINNET Results For Lorigerlimab In Advanced Clear Cell Gynecologic Cancer CI
10-24 MacroGenics, Inc. Announces Positive Interim Phase 1 Results For MGC026 And Plans To Initiate Front-Line Combination Study In SCCHN CI
10-16 MacroGenics Says First Patient Dosed in Phase 1 Study of MGC030 for Advanced Solid Tumors MT
10-16 MacroGenics, Inc. Announces First Patient Dosed In Phase 1 Study Of MGC030 In Patients With Advanced Solid Tumors CI
08-17 B. Riley Raises Price Target on MacroGenics to $11 From $9, Keeps Buy Rating MT
08-14 MacroGenics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
08-12 Macrogenics, Inc. and Gilead Sciences, Inc. Announce Achievement of $10 Million Milestone Following Gilead Sciences, Inc.?S Exercise of Option to License Preclinical Bispecific Program CI
07-24 MacroGenics, Inc. Provides Clinical Update on Ongoing Phase 1 Study for MGC026 CI
07-09 Macrogenics, Inc. Announces Resignation of Karen Ferrante from Director Role, Effective September 1, 2026 CI
07-03 MacroGenics Closes Sale of Manufacturing Operations to Bora Pharmaceuticals MT
07-02 Bora Biologics USA, LLC completed the acquisition of Good Manufacturing Practice Drug Substance Manufacturing Operations of MacroGenics, Inc.. CI
06-30 MacroGenics, Inc.(NasdaqGS:MGNX) added to Russell Small Cap Comp Growth Benchmark CI
06-30 MacroGenics, Inc.(NasdaqGS:MGNX) added to Russell 2500 Growth Benchmark CI
1 day+0.84%
1 week+6.67%
1 month-33.33%
3 months-34.96%
6 months-23.32%
Current year+49.07%
1 week 2.16
Extreme 2.1579
2.59
1 month 1.93
Extreme 1.93
3.86
Current year 1.58
Extreme 1.58
5.08
1 year 1.29
Extreme 1.29
5.08
3 years 0.99
Extreme 0.98965
21.88
5 years 0.99
Extreme 0.98965
22.68
10 years 0.99
Extreme 0.98965
36.48
Manager TitleAgeSince
Chief Executive Officer 53 13/08/2025
Director of Finance/CFO 59 01/05/2008
Chief Tech/Sci/R&D Officer 61 -
Director TitleAgeSince
Director/Board Member 73 01/09/2001
Director/Board Member 53 13/08/2025
Director/Board Member 62 01/10/2004
Date Insider Type Main position Quantity % Market Cap. Importance
6/10/26 Exercice

Chief Technology Officer

16,000 0.0251%
19/8/26 Sell

General Counsel

-31,105 0.0489%
17/8/26 Exercice

Chief Technology Officer

80,000 0.1259%
Change 5-day change 1-year change 3-year change Capi.($)
+0.84%+6.67%+44.58%-54.63% 153M
-0.62%-1.87%+42.87%+67.17% 63.77B
+0.35%+3.20%+14.40%+73.89% 56.37B
+0.53%+1.96%+16.24%+102.20% 54.62B
-2.81%-4.31%+23.50%+48.51% 44.06B
-0.33%-1.93%+19.28%+104.26% 42.11B
+0.55%+2.31%+225.14%+840.10% 41B
+3.27%+47.96%+112.84%+91.02% 34.92B
+1.22%-1.44%+14.57%+47.05% 32.82B
+0.89%+20.55%-40.62%+350.50% 24.7B
Average +0.39%+7.45%+47.28%+167.01% 39.45B
Weighted average by Cap. +0.18%+5.44%+47.99%+173.32%

Financials

2026 *2027 *
Net sales 108M 96.9M 89.13M 80.76M 151M 10.27B 154M 1.06B 427M 5.4B 406M 397M 17.04B 90.61M 81.15M 74.64M 67.63M 126M 8.6B 129M 890M 357M 4.53B 340M 333M 14.27B
Net income -88.7M -79.44M -73.07M -66.21M -124M -8.42B -126M -871M -350M -4.43B -333M -326M -13.97B -138M -124M -114M -103M -193M -13.11B -196M -1.36B -545M -6.9B -518M -507M -21.75B
Net Debt - -
Projected Income Statement - Annual - MacroGenics, Inc.
Logo MacroGenics, Inc.
MacroGenics, Inc. is a biopharmaceutical company. The Company is focused on developing antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates from its proprietary suite of antibody technology platforms. It is developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which are referred to as DART and TRIDENT molecules). It has multiple proprietary product candidates. These include three clinical-stage ADCs incorporating a novel topoisomerase I inhibitor (TOP1i)-based linker-payload: MGC026, which targets B7-H3; MGC028, which targets ADAM9, and MGC030, which is directed against an undisclosed target. It is also developing lorigerlimab, a clinical-stage bispecific DART molecule targeting the immune checkpoint receptors PD-1 and CTLA-4. In addition, it is also developing multiple preclinical-stage ADC and next-generation T-cell engager programs.
Employees
293
Date Price Change Volume
30/10/26 US$2.400 +0.84% 1,182,982
29/10/26 US$2.380 -3.64% 744,479
28/10/26 US$2.470 +1.23% 1,414,425
27/10/26 US$2.440 +11.42% 2,120,069
26/10/26 US$2.190 -2.67% 2,606,646
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - MacroGenics, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
2.400USD
Average target price
8.000USD
Spread / Average Target
+233.33%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - MacroGenics, Inc.
  1. Stock Market
  2. Stocks
  3. MGNX Stock